Newer Oral Anticoagulants and Available Reversal Agents. Cara L. Leos, Pharm D, BCPS AQ Cardiology Baptist Medical Center South Montgomery, AL
|
|
- Hugh Wilkins
- 5 years ago
- Views:
Transcription
1 Newer Oral Anticoagulants and Available Reversal Agents Cara L. Leos, Pharm D, BCPS AQ Cardiology Baptist Medical Center South Montgomery, AL
2 Disclosure Speakers bureau Boehringer Ingelheim As each of the newer agents is discussed, they will be presented in order of appearance on the US market, not in any order of personal preforance. We will be discussing 1 investigational new drug
3 Objectives Describe novel anticoagulants and their characteristics Compare differences between new anticoagulants Assess bleeding risk of new anticoagulants Explain different treatment options for bleeding patients Discuss specific reversal agents
4 Your Practice How many of you practice in: A. Community Setting B. Health System Setting C. Other How many are: A. Pharmacists B. Technicians C. Interns
5 Hemostasis Circulatory hemostasis components Vessel walls Plasma proteins / clotting factors Platelets Microparticles / tissue factors Activated by endothelial changes Trauma or injury of some sort Pathological (secondary to certain disease states / physical conditions)
6 Hemostasis Big Picture Reactionary to vascular changes Rapid formation of platelet and fibrin plug at the site of injury During formation, triggers it s own dissolution (fibrinolysis) When normal regulatory systems become overwhelmed: pathologic
7 Thrombosis Pathogenesis Virchow triad Endothelial injury Stasis or turbulence of blood flow Atrial fibrillation Prosthetic heart valves Immobility Blood hyper coagulability Factor V Leiden defect Protein C or S deficiency Antiphopholipid antibody syndrome
8 Downloaded from: Robbins & Cotran Pathologic Basis of Disease (on 17 March :02 PM) 2005 Elsevier 8
9 Downloaded from: Robbins & Cotran Pathologic Basis of Disease (on 17 March :02 PM) Elsevier
10 Downloaded from: Robbins & Cotran Pathologic Basis of Disease (on 17 March :02 10PM) 2005 Elsevier
11 Downloaded from: Robbins & Cotran Pathologic Basis of Disease (on 17 March :02 PM) 11
12 But it s not all about platelets
13
14 Coagulation Factors Procoagulants IIa (thrombin) Ia (fibrin) Xa Va VIIa IXa Anticoagulants Protein C Protein S TFPI t PA Antithrombin (AT)
15 Pop quiz What factors does warfarin inhibit? A. II, V, VII, IX (2, 5, 7, 9), Proteins C & S B. II, V, X (2, 5, 10), Proteins C & S C. II, VII, IX, X (2, 7, 9, 10) Proteins C & S D. Dear Lord, I don t remember. Please make it stop!
16 And in the End
17 When good clots go bad
18 Thrombosis Pathologic response to hemostasis Inappropriate activation of the normal hemostatic processes Formation of a thrombosis in an uninjured vessel Occlusion of the vasculature by thrombis formation after relatively minor endothelial damage
19 Thrombosis Can result in emboli if dislodged Pulmonary embolism Deep vein thrombosis (DVT) Myocardial infarction Stroke Dissolution Fibrinolytic pathway Surgery Drug therapy 19
20 Is it a NOAC or a DOAC?
21 DOAC s on the Market In order of appearance Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa )
22 DOAC MOA
23 Current U.S. Indications Stroke prevention in afib All four agents Treatment of venous thromboembolism (VTE) All four agents* Prevention of VTE (surgical) Apixaban, dabigatran, rivaroxaban Secondary prevention of VTE apixaban
24 Direct Thrombin Inhibitor DABIGATRAN (PRADAXA )
25 Dabigatran: afib 150mg PO BID Dose found to be superior compared to warfarin for stroke risk reduction 75mg PO BID if: CrCl 30 50ml/min PLUS dronedarone or ketoconazole CrCl 15 30ml/min (d/c drug if receiving P gp inhibitor) Not to be used in CrCl < 15ml/min
26 Dabigatran and FDA 110mg dose: Found to be non inferior to warfarin for stroke reduction, but less bleeding than the 150mg dose. 110mg dose not FDA approved for afib 75mg dose: Not studied for endpoints in humans Data extrapolated from kinetics models FDA approved
27 Dabigatran: VTE Treatment 150mg PO BID after 5 10days of parenteral anticoag (UFH/LMWH) UFH/LMWH on own for 5 10 days Discontinue UFH/LMWH Start dabigatran at next dose due Safe for CrCl > 30ml/min except: CrCl 30 50ml/min PLUS P gp inhibitors (d/c dabigatran)
28 Dabigatran: VTE Prevention Post op hip replacement surgery 110mg PO X 1 taken 1 4 hours after surgery & hemostasis achieved 220mg PO qday for days If 110mg dose not administered day of surgery, start 220mg regimen on POD 1 Safe for CrCl > 30ml/min except: CrCl 30 50ml/min PLUS P gp inhibitors (d/c dabigatran)
29 Which of the following is TRUE? A. Dabigatran 110mg dose proved superiority over warfarin in stroke reduction secondary to afib. B. Dabigatran can be used in patients on hemo or peritoneal diaylsis C. Dabigatran is now approved post hip and knee replacement in the US D. Dabigatran can be started after the completion of 5 10days UFH/LMWH therapy in acute VTE
30 Dabigatran: Tidbits Cannot be removed from stock bottle during dispensing Need easy off? Pop the top! Unit dose packaging only if to be used in pill boxes Swallow whole! Other administration can result in increased exposure to drug and increased ADE s Will increase an INR
31 Factor Xa Inhibitor RIVAROXABAN (XARELTO )
32 Rivaroxaban: afib 20mg PO qday with evening meal Bioavailability ~ 60% fasting 15mg PO qday with evening meal if: CrCl 15 50ml/min Not to be used CrCl < 15ml/min
33 Rivaroxaban: VTE Treatment 15mg po BID (breakfast/supper) X 21 days, then 20mg po qday with evening meal Provoked VTE: 3 months of therapy Unprovoked: 3 6 months of therapy Can be continued at 20mg po qday for up to years if thought necessary Secondary prevention
34 Rivaroxaban: VTE Prevention Post op hip and knee replacement 10mg po qday (no meal restrictions) Started 6 10hr post op & hemostasis established Knee: days Hip: 35 days Avoid use in CrCl < 30ml/min
35 Rivaroxaban: Tidbits Has some data in extremes of weight Less than 50 and up to 200kg Can be crushed Given in applesauce/pudding Suspended in 50ml H2O & given via feeding tube Still must have food/tube feeds for afib/vte doses immediately after Tablets are not scored Will increase an INR
36 Factor Xa Inhibitor APIXABAN (ELIQUIS )
37 Apixaban: afib 5mg PO BID 2.5mg PO BID if any 2 of the following: Age 80+ Bodyweight 60kg or less SCr 1.5mg/dl + ESRD on HD 5mg po BID 2.5mg PO BID if age 80+ or weight less than 60kg
38 Apixaban: VTE Treatment 10mg PO BID X 7 days, then 5mg PO BID No renal dose adjustment, but patients with SCr 2.5+ or CrCl < 25 were not included in the trials. Clinical decision regarding risk of clot vs risk of bleed. Can be continued at 2.5mg PO BID after 6 months of therapy to reduce secondary clot risk
39 Apixaban: VTE Prevention Post op hip and knee replacement 2.5mg PO BID Started 12 24hr post op Knee: 12 days Hip: 35 days CrCl 15 29ml/min: use with caution CrCl < 15 and dialysis: not recommended
40 Apixaban: Tidbits FOCUS patients 80+!!! These are patients at highest risk for bleeding and are routinely low bodyweight or renally impaired!! Can be crushed Given in applesauce/pudding Suspended in 60ml D5W for feeding tube administration Not dependent on food for absorption Will increase an INR
41 Factor Xa Inhibitor EDOXABAN (SAVAYSA )
42 Edoxaban: afib 60mg PO qday 30mg PO qday if: CrCl 15 50ml/min Do not use in: CrCl < 15ml/min CrCl > 95ml/min!! AUC diminished in normal renal function resulting in potential diminished effectiveness!!! Increased risk of stroke
43 Edoxaban: VTE Treatment 60mg PO qday after 5 10days of parenteral anticoag (UFH/LMWH) UFH/LMWH on own for 5 10 days Discontinue UFH/LMWH Start edoxaban at next dose due 30mg PO qday after UFH/LMWH if: Body weight 60kg or less CrCl 15 50ml/min P gp inhibitors: verapamil, quinidine, azithro /clarithromycin or itra /ketoconazole
44 Edoxaban: Tidbits Only factor Xa inhibitor that can be used with phenytoin or phenobarbital No info regarding feeding tube administration Not food dependent Renal function, renal function, renal function watch your young afib pts! Will increase an INR
45 Which of the following is TRUE? A. Dabigatran needs to be swallowed whole. B. Rivaroxaban & apixaban are safe to use with phenytoin or phenobarbitol C. Edoxaban must be taken with food. D. Rivaroxaban is the only DOAC with dialysis dosing.
46 Comparison of Oral Agents Agent Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target IIv, VIIa, IXa, Xa IIa Xa Xa Xa Prodrug No Yes No No No Peak effect 4 5 days 1.5 3hr 2 4hr 1 3hr 1 2hr Half life 40hr 12 17hr 5 9hr 9 14hr 9 11hr Renal elim. None 80% 33% 25% 35 50% Dialyzable No Yes No No No Interactions MANY P gp CYP 3A4, P gp CYP3A4, P gp P gp Monitoring Yes No No No No Antidote Vitamin K, FFP Idarucizumab In study In study In study Cove CL, Hyleck EM. J Am Heart Assoc 2013; 2:e000136
47 Drug in the pipeline Betrixaban Factor Xa inhibitor Currently study: VTE prophylaxis in the medically ill Replacement for LMWH? Inpatient and post discharge while convalescing Estimated market share: 30 million people
48 Therapeutic Drug Monitoring
49 These ain t your momma s warfarin ALL DOAC s increase the INR No relationship to degree of anticoagulation Don t be fooled! Vitamin K isn t going to help PTT: can be used to assess degree of anticoagulation in association with time of last dose
50 These ain t your momma s warfarin Dabigatran aptt (2.5 X reference range) may indicate overanticoagulation Ecarin clotting test (ECT) Academic medical centers Thrombin time (TT) Most reliable (direct thrombin inhibitor) Likely send out lab
51 These ain t your momma s warfarin Factor XaInhibitors Anti factor Xa level Drug/reagent specific ask your lab Values have not been established for DOAC s What levels are therapeutic? How do you adjust?
52 These ain t your momma s warfarin All anticoagulants: CBC Chemistries/renal function AST/ALT Patients should be aware of: Abnormal bruising/bleeding Fatigue, dizziness, shortness of breath
53 Reversal Agents
54 Classics and Bestsellers Vitamin K (PO or IV) FFP (Fresh frozen plasma) Prothrombin Complex Concentrate Factors II, VII, IX, X, proteins C & S Brand name Kcentra None of which has been found effective in DOAC s Dabigatran: hemodialysis
55 Idarucizumab (Praxbind ) Approved for use October 2015 Monoclonal (humanized) antibody for dabigatran Will not work on bivalirudin 5g total infusion (2, 2.5g bottles) Fast onset Use: Need for emergent surgery or life-threatening bleeds
56 Pipeline: Andexanet alfa Modified factor Xa molecule Becomes a decoy for endogenous factor Xa Anticoagulant binds to decoy preventing anticoagulation Will also inhibit actions of enoxaparin and fondaparinux Normally bind to ATIII and potentiate the inhibition of factor Xa
57 Pipeline: Andexanet alfa Phase III trials completed Attempting accelerated approval from the FDA Intended indication: Emergent surgery Life threatening bleed
58 Reversal Agents and Role of Pharmacy Good medication history as possible Last refill, last dose Other potentiating factors including OTC drugs/herbals and antiplatelets Basic PK/PD knowledge Laboratory interpretation Protocol development
59 Case Independent pharmacy medications for a local nursing home Access to basic patient information and all medications provided to the residents. You receive a telephone RX for Mr Smith, a 72yo resident, for vitamin K and the physician wants you to dose it for him.
60 Mr Smith Recently hospitalized for a PE Now on apixaban 5mg PO BID Routine labs resulted today SCr 1.2 CrCl 42ml/min H/H 13.2/38 PT/INR 35.31/3.21 No recent falls or reports of bleeding
61 Mr Smith Based on this information you recommend: A. Vitamin K 5mg IM X 1 B. Vitamin K 1mg IV X 1 C. Vitamin K 2.5mg PO X 1 D. No vitamin K an elevated INR with apixaban is to be expected
62 Case 2 Mrs Rodriguez arrives at the ED where you work. You receive a call from the ED doctor to dose Kcentra. 53yo female on dabigatran 150mg po BID for afib. Last dose yesterday at bedtime PT/INR 82.61/7.51 H/H 12.3/36.9 SCr 2.7; CrCl 42 ml/min
63 Mrs Rodriguez Presenting to the ED with congestion and sinus pressure unrelieved with OTC agents (X 3 days) Denies abnormal bruising/bleeding You quickly review the remaining information available nothing else pertinent
64 Mrs Rodriguez You recommend: A. Kcentra weight based dosing for INR > 6 B. Vitamin K and FFP because that is the recommended treatment in this case C. No action: patient does not meet criteria for dabigatran reversal D. Praxbind 2.5g IV X 2
65 Mrs Rodriguez What if it s 3am and she was instead involved in a motor vehicle accident with her last dose of dabigatran 4 hours ago? She has massive internal injuries and is being taken to the O.R?
66 Mrs Rodriguez You recommend: A. Kcentra weight based dosing for INR > 6 B. Vitamin K and FFP because that is the recommended treatment in this case C. No action: patient does not meet criteria for dabigatran reversal D. Praxbind 2.5g IV X 2
67 Recommended References Acforum.org Free access Guidelines including recent clinical guidance publication Protocols/procedures Webinars monthly on anticoag topics AC Forum Bootcamp information
68 Recommended References Apps Xarelto Anticoag Evaluator (From ACC) MAQI2 Anticoagulation Toolkit Afib Educator
69 Newer Oral Anticoagulants and Available Reversal Agents Cara L. Leos, Pharm D, BCPS AQ Cardiology Baptist Medical Center South Montgomery, AL
Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationThey re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants)
They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants) Daniel B. DiCola, MD Paul W. Ament, PharmD Daniel DiCola, MD ddicola@excelahealth.org Faculty: Latrobe Area Hospital, Excela Health
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationUpdate with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist
Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist Peter Thomson, Pharm D. Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Clinical
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationManaging Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationReversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding
Reversal of Direct Oral Anticoagulants Cameron D Griffiths, MD, FRCPC Clinical Assistant Professor Division of Hematology UBC Objectives Review efficacy and safety data for Direct Oral Anticoagulants (DOACs)
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationIndividualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationA Cascade of Updates: Hot Topics in Anticoagulation
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More information3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test
Objectives for Pharmacists Stop the Bleeding! New Reversal Agents Gary D Peksa, Pharm.D., BCPS Clinical Pharmacy Specialist, Emergency Medicine Rush University Medical Center Review current strategies
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationNovel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology
Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationLeading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient
Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient Emily Hutchison, PharmD BCPS Clinical Pharmacy Specialist, Trauma/Adult
More informationDavid Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationDisclosure and Conflict of Interest
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationAcute Care: Understanding Direct Oral Anticoagulants (DOACs)
Acute Care: Understanding Direct Oral Anticoagulants (DOACs) National Conference for Nurse Practitioners (NCNP) October 11, 2017 John Togami, PharmD, PhC Pharmacist Clinician - Outpatient Anticoagulation
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationTHROMBOSIS AND THE CLOTTING CASCADE AND YOU. William Houck Shenandoah Oncology
THROMBOSIS AND THE CLOTTING CASCADE AND YOU William Houck Shenandoah Oncology WE LL TALK ABOUT Remembering the clotting cascade and the key players Tests for hypercoagulable states & when to do Remembering
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationHemostasis and Thrombosis for Primary Care Providers: An Update. Andrew D. Leavitt, MD. May 21, Topic Outline. Direct Oral Anti-Coagulants DOACs
Hemostasis and Thrombosis for Primary Care Providers: An Update 43 nd Annual Advances in Internal Medicine Andrew D. Leavitt, MD May 21, 2015 Topic Outline Direct Oral Anti-Coagulants DOACs Update and
More informationAdvances in Anticoagulation
May 18, 2017 Advances in Anticoagulation Wei Ling Lau, MD Assistant Professor, Nephrology University of California, Irvine Talk Outline High stroke risk in CKD population Warfarin off-target effects on
More informationThe Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.
The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants
More informationAre the days of Warfarin numbered?
2 nd SAVTE Symposium Are the days of Warfarin numbered? YES Dr. Mohamed A. Abdelaal, MD, FRCPath, FRCPI Consultant Haematologist King Abdulaziz Medical City - Jeddah, Saudi Arabia 1 3 May 2012, Casablanca,
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationEverything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science
Everything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science Center at San Antonio Department of Pharmacotherapy
More informationMEDICATION MANAGEMENT IN VTE FROM CONVENTIONAL TO NEW
MEDICATION MANAGEMENT IN VTE FROM CONVENTIONAL TO NEW Presented by: David B. Coriale RPh. Pharm D BCPS Clinical Pharmacy Manger Oneida Healthcare Oneida, NY WWW.HEALTHUNITS.COM Presentation John is a
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationNovel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015
Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)
More informationDabigatran 101: Community Pharmacists. Peter Thomson Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority
Dabigatran 101: Community Pharmacists. Peter Thomson Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Objectives At the end of this session, you should be able to: Describe
More informationEmergent Anticoagulation Reversal
U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationlaboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie.
laboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie. Disclosures Malake Naboulsi declare to meeting attendees that
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationEmergency Management of Patients on Direct Oral Anticoagulants (DOACs)
Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October
More informationTSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
More informationA Brief History of the World of Anticoagulation
A Brief History of the World of Anticoagulation Allison Burnett, PharmD, CACP, PhC Clinical Assistant Professor- UNM College of Rx Antithrombosis Stewardship Pharmacist University of New Mexico Hospital
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationWelcome to the New England QIN-QIO Medication Safety Webinar!
Welcome to the New England QIN-QIO Medication Safety Webinar! Thank you for joining. Our presentation will begin shortly. If you haven t already, please dial in to the audio line: 888-895-6448 Passcode:
More information